Loading...
•
Dec 31, 2020
Lineage Q4 2020 Earnings Report
Reported fourth quarter and full year 2020 financial results.
Key Takeaways
Lineage Cell Therapeutics reported a net income of $2.0 million for the fourth quarter of 2020, compared to a net loss of $4.5 million for the same period in 2019. Total revenues for the quarter were $0.4 million, a decrease of $0.8 million compared to the same period in 2019. Cash, cash equivalents, and marketable securities totaled $41.6 million as of December 31, 2020.
Lineage achieved significant clinical, manufacturing, and business milestones in 2020.
The company added $35.9 million in new capital through equity and marketable securities sales.
Lineage believes it is well funded into 2023 due to cost savings and fundraising.
Net income attributable to Lineage for the quarter was $2.0 million, or $0.01 per share, compared to a net loss of ($4.5) million, or ($0.03) per share in 2019.
Forward Guidance
The Company anticipates that net operational spend for 2021 will be approximately $20.0 to $22.0 million, which is similar to 2020 spending levels. The Company believes that it is well funded into 2023 as a result of sustained cost savings initiatives in 2020 and recent fundraising activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...